Indication
Advanced Systemic Mastocytosis
4 clinical trials
5 products
Product
DCC-2618Clinical trial
A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, Efficacy, and Pharmacokinetics in Patients With Advanced MalignanciesStatus: Completed, Estimated PCD: 2022-04-29
Product
BLU-263Clinical trial
A Phase 1/2, Open-label, 2-arm Study Evaluating BLU-263 as Monotherapy and in Combination With Azacitidine, in Patients With KIT Altered Hematologic MalignanciesStatus: Recruiting, Estimated PCD: 2029-11-30
Product
AzacitidineProduct
bezuclastinibClinical trial
An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic MastocytosisStatus: Active (not recruiting), Estimated PCD: 2026-01-31
Product
AvapritinibClinical trial
A Phase 2 Open-Label, Multicenter Clinical Study of the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Profiles of CGT9486 as a Single Agent in Patients With Advanced Systemic MastocytosisStatus: Recruiting, Estimated PCD: 2025-01-01